Literature DB >> 12521073

Ultrasound imaging for external-beam prostate treatment setup and dosimetric verification.

T Falco1, G Shenouda, C Kaufmann, I Belanger, C Procaccini, C Charrois, M Evans.   

Abstract

Ultrasound (US) image-guided patient positional verification was performed daily on four prostate cancer patients using the BAT system (NOMOS Corporation, CA). The BAT system has shown that the prostate can shift by as much as 1 cm from its intended position in any direction. Furthermore, the daily shifts measured by the BAT system were included into the treatment planning system to assess changes in prostate dose coverage. Dose volume histograms were used to compare the dosimetry between the ideal patient set-up situation (prostate always positioned correctly) and that taking all patient daily shifts into consideration. Daily patient shifts on the order of magnitudes measured, can significantly and adversely affect dosimetric coverage, therefore an US-based patient positioning system is required for improving the therapeutic ratio.

Entities:  

Mesh:

Year:  2002        PMID: 12521073     DOI: 10.1016/s0958-3947(02)00144-9

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  3 in total

1.  First report of robot-assisted transperineal fusion versus off-target biopsy in patients undergoing repeat prostate biopsy.

Authors:  S Kaufmann; J Mischinger; B Amend; S Rausch; M Adam; M Scharpf; F Fend; U Kramer; M Notohamiprodjo; K Nikolaou; A Stenzl; J Bedke; S Kruck
Journal:  World J Urol       Date:  2016-11-15       Impact factor: 4.226

2.  Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer.

Authors:  S Kaufmann; J Bedke; S Gatidis; J Hennenlotter; U Kramer; M Notohamiprodjo; K Nikolaou; A Stenzl; S Kruck
Journal:  World J Urol       Date:  2015-08-13       Impact factor: 4.226

3.  Dose perturbations from implanted helical gold markers in proton therapy of prostate cancer.

Authors:  Annelise Giebeler; Jonas Fontenot; Peter Balter; George Ciangaru; Ronald Zhu; Wayne Newhauser
Journal:  J Appl Clin Med Phys       Date:  2009-01-27       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.